TEVA PHARMACEUTICAL INDUSTRIES LTD files DEF 14A

This proxy statement outlines proposals for Teva Pharmaceutical Industries Limited's 2026 Annual Meeting of Shareholders, including the election of a director, an advisory vote on executive compensation, and the appointment of the independent auditor. Shareholders will also consider Teva’s annual consolidated financial statements for the year ended December 31, 2025.